Kanwal Raghav

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018

Jonathan M. Loree, Seerat Anand, Arvind Dasari et al. · JAMA Oncology · 2019 · 569 citations · Full text

Medicine, Oncology, Population Health Sciences +17

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Funda Meric‐Bernstam, Herbert I. Hurwitz, Kanwal Raghav et al. · The Lancet Oncology · 2019 · 564 citations

Medicine, Oncology, Pharmacology +14

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers

Rachna T. Shroff, Milind Javle, Lianchun Xiao et al. · JAMA Oncology · 2019 · 473 citations · Full text

Medicine, Oncology, Pharmacology +11

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav et al. · The Lancet Oncology · 2021 · 413 citations

Medicine, Oncology, Pharmacology +11

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

Scott Kopetz, Katherine A. Guthrie, Van K. Morris et al. · Journal of Clinical Oncology · 2020 · 391 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13